Skip to Content
Merck
All Photos(1)

Documents

A0325450

Alfacalcidol

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

1α-Hydroxyvitamin D3, 1α-Hydroxycholecalciferol, Alfacalcidol

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C27H44O2
CAS Number:
41294-56-8
Molecular Weight:
400.64
MDL number:
MFCD00868328
UNSPSC Code:
41116107
PubChem Substance ID:
329770599
NACRES:
NA.24

biological source

synthetic

grade

pharmaceutical primary standard

Agency

EP

API family

alfacalcidol

form

solid

manufacturer/tradename

EDQM

technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

−20°C

SMILES string

CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C3\C[C@@H](O)C[C@H](O)C3=C

InChI

1S/C27H44O2/c1-18(2)8-6-9-19(3)24-13-14-25-21(10-7-15-27(24,25)5)11-12-22-16-23(28)17-26(29)20(22)4/h11-12,18-19,23-26,28-29H,4,6-10,13-17H2,1-3,5H3/b21-11+,22-12-/t19-,23-,24-,25+,26+,27-/m1/s1

InChI key

OFHCOWSQAMBJIW-AVJTYSNKSA-N

Gene Information

human ... VDR(7421)

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the authority of the issuing pharmacopoeia. For further information and support please go to the website of the issuing pharmacopoeia.

Alfacalcidol is an active metabolite of vitamin D, used as a vitamin supplement due to it longer half-life. It is found to be effective in regulating calcium balance/bone metabolism.

Application

This European Pharmacopoeia reference standard is intended for use only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

Synthetic vitamin D3 analog that is metabolized to 1,25-dihydroxycholecalciferol. Inhibits bone resorption and stimulates bone formation. Supresses parathyroid hormone secretion by bovine parathyroid cells.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Pictograms

Skull and crossbones
GHS06

Signal Word

Danger

Hazard Statements

H300

Hazard Classifications

Acute Tox. 1 Oral

Storage Class Code

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Noboru Kubodera
Mini reviews in medicinal chemistry, 9(12), 1416-1422 (2009-11-26)
Many readers may have only a vague idea about vitamin D. This is made complicated, in part, because it is also expressed with suffixes such as vitamin D(2) or vitamin D(3). Otherwise the prefix of "active" is also occasionally used.
Siobhan O'Donnell et al.
Journal of bone and mineral metabolism, 26(6), 531-542 (2008-11-04)
Our objective was to conduct a systematic review on the benefits and harms of calcitriol and alfacalcidol in the reduction of fracture and fall risk. Randomized controlled trials (RCTs) comparing these agents to placebo or calcium and reporting fracture and
Florent Richy et al.
Aging clinical and experimental research, 17(2), 133-142 (2005-06-28)
Alfacalcidol (1-alpha-hydroxyvitamin D3) is a non-endogenous analog of vitamin D which can bypass the renal and intestinal regulatory mechanisms that control the production of calcitriol (1,25-hydroxyvitamin D3, the active form of vitamin D, D-Hormone). Alfacalcidol may be metabolized into calcitriol
J D Ringe et al.
Rheumatology international, 28(2), 103-111 (2007-08-02)
While in other chronic diseases combined treatment regimens are the rule there is a lack of reported experience or study data on combining different specific drugs to treat osteoporosis. Significant differences in the mode of action (MOA) of the substances
P Sambrook
Calcified tissue international, 65(4), 341-343 (1999-09-15)
There is increasing evidence that D-hormones (active vitamin D metabolites) are effective agents in preventing posttransplantation bone loss of various organs. This effect may relate to several mechanisms including reversal of secondary hyperparathyroidism from cyclosporine, reversal of corticosteroid effects on
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service